CN102066403B - 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 - Google Patents
抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 Download PDFInfo
- Publication number
- CN102066403B CN102066403B CN200980117151.2A CN200980117151A CN102066403B CN 102066403 B CN102066403 B CN 102066403B CN 200980117151 A CN200980117151 A CN 200980117151A CN 102066403 B CN102066403 B CN 102066403B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- polypeptide
- sequence
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000890 antigenic effect Effects 0.000 title abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 106
- 229920001184 polypeptide Polymers 0.000 claims abstract description 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 75
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 15
- 238000012216 screening Methods 0.000 claims abstract description 8
- 229960005486 vaccine Drugs 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 34
- 210000004408 hybridoma Anatomy 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 6
- 238000011725 BALB/c mouse Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 108010007337 Azurin Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 abstract description 14
- 208000030507 AIDS Diseases 0.000 abstract description 13
- 230000027455 binding Effects 0.000 abstract description 12
- 230000000692 anti-sense effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000001270 agonistic effect Effects 0.000 abstract description 2
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 58
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 52
- 125000000539 amino acid group Chemical group 0.000 description 44
- 108700012411 TNFSF10 Proteins 0.000 description 32
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 30
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 8
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 108010049207 Death Domain Receptors Proteins 0.000 description 5
- 102000009058 Death Domain Receptors Human genes 0.000 description 5
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 239000011022 opal Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 3
- 238000010523 cascade reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229940124321 AIDS medicine Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000001314 canonical amino-acid group Chemical group 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (11)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2009/071164 WO2010111842A1 (zh) | 2009-04-03 | 2009-04-03 | 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102066403A CN102066403A (zh) | 2011-05-18 |
CN102066403B true CN102066403B (zh) | 2014-10-08 |
Family
ID=42827474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980117151.2A Active CN102066403B (zh) | 2009-04-03 | 2009-04-03 | 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8790663B2 (zh) |
EP (1) | EP2415781A4 (zh) |
JP (1) | JP2012522492A (zh) |
CN (1) | CN102066403B (zh) |
AU (1) | AU2009343398B2 (zh) |
CA (1) | CA2749512A1 (zh) |
WO (1) | WO2010111842A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2842546A4 (en) | 2012-04-27 | 2015-12-30 | Univ Tokyo | UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION |
JP6644326B2 (ja) | 2017-08-31 | 2020-02-12 | 国立大学法人 東京大学 | 核酸搭載ユニット型ポリイオンコンプレックス |
CN115974976B (zh) * | 2022-11-23 | 2024-06-04 | 华中科技大学 | 拮抗多肽及用于制备抗急性肾损伤药物的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1275162A (zh) * | 1997-03-17 | 2000-11-29 | 人类基因组科学公司 | 包含死亡结构域的受体-5 |
US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
CN1610696A (zh) * | 2001-12-20 | 2005-04-27 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
CN1635908A (zh) * | 2001-05-25 | 2005-07-06 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
CN1673232A (zh) * | 2004-08-19 | 2005-09-28 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体(ad5-10)及其制法与用途 |
CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
CN101300273A (zh) * | 2005-08-31 | 2008-11-05 | 安姆根有限公司 | Trail受体2多肽和抗体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0445606B1 (en) * | 1990-02-27 | 1997-01-22 | The Agency of Industrial Science and Technology | Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides |
CN1239516C (zh) | 2002-02-08 | 2006-02-01 | 中国医学科学院基础医学研究所 | 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途 |
DE602004019701D1 (de) * | 2003-05-09 | 2009-04-09 | Genentech Inc | Peptide welche an Apo2L (Trail) Rezeptoren binden und Verwendungen davon |
PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
-
2009
- 2009-04-03 JP JP2012502419A patent/JP2012522492A/ja active Pending
- 2009-04-03 AU AU2009343398A patent/AU2009343398B2/en active Active
- 2009-04-03 CN CN200980117151.2A patent/CN102066403B/zh active Active
- 2009-04-03 US US13/257,156 patent/US8790663B2/en active Active
- 2009-04-03 WO PCT/CN2009/071164 patent/WO2010111842A1/zh active Application Filing
- 2009-04-03 EP EP09842499A patent/EP2415781A4/en not_active Withdrawn
- 2009-04-03 CA CA2749512A patent/CA2749512A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
CN1275162A (zh) * | 1997-03-17 | 2000-11-29 | 人类基因组科学公司 | 包含死亡结构域的受体-5 |
CN1635908A (zh) * | 2001-05-25 | 2005-07-06 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
CN1610696A (zh) * | 2001-12-20 | 2005-04-27 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
CN1673232A (zh) * | 2004-08-19 | 2005-09-28 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体(ad5-10)及其制法与用途 |
CN101300273A (zh) * | 2005-08-31 | 2008-11-05 | 安姆根有限公司 | Trail受体2多肽和抗体 |
CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US8790663B2 (en) | 2014-07-29 |
AU2009343398A1 (en) | 2010-10-07 |
EP2415781A1 (en) | 2012-02-08 |
AU2009343398B2 (en) | 2015-01-29 |
US20120271034A1 (en) | 2012-10-25 |
CA2749512A1 (en) | 2010-10-07 |
EP2415781A4 (en) | 2012-10-17 |
JP2012522492A (ja) | 2012-09-27 |
CN102066403A (zh) | 2011-05-18 |
WO2010111842A1 (zh) | 2010-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2874486C (en) | Murine anti-ny-eso-1 t cell receptors | |
US11713342B2 (en) | Compositions and methods for targeted cytokine delivery | |
Liang et al. | Characterization of huJAM: evidence for involvement in cell-cell contact and tight junction regulation | |
CN106279409A (zh) | 一种寨卡病毒人源单克隆抗体及其应用 | |
EP4353745A1 (en) | A group of b7h3 monoclonal antibodies and medical use thereof | |
CN110121505A (zh) | 嵌合抗原受体和表达其的自然杀伤细胞 | |
CN110734493B (zh) | 抗pd-1抗体及其用途 | |
CN105330740A (zh) | 抗pd-1抗体及其应用 | |
CN106536564A (zh) | 靶向cd‑19的嵌合抗原受体 | |
EA026129B1 (ru) | АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ | |
JPH06507398A (ja) | Hiv感染治療のための異種複合抗体 | |
CN115710311A (zh) | 冠状病毒的抗体或其抗原结合片段 | |
CN101563098A (zh) | Il-17a/f异二聚体多肽及其治疗用途 | |
CN110078818A (zh) | 人cd30配体抗原结合蛋白 | |
US20150368316A1 (en) | A selective high-affinity immune stimulatory reagent and uses thereof | |
CN1639194A (zh) | 抗癌抗体 | |
CN102066403B (zh) | 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 | |
Garni-Wagner et al. | 4-1BB Is Expressed on CD45RAhiROhiTransitional T Cell in Humans | |
CN113179631A (zh) | 通过临近使能反应疗法开发的共价蛋白质药物 | |
Borenstein-Katz et al. | Differential antibody-based immune response against isolated GP1 receptor-binding domains from Lassa and Junin viruses | |
CN112538116A (zh) | 一组4-1bb单克隆抗体及其医药用途 | |
US9399667B2 (en) | Peptides derived from cytotoxicity receptor natural killer protein 44 NKP44 | |
CN101864398B (zh) | 一种抗促性腺激素释放激素受体的单克隆抗体与应用 | |
CN110167959A (zh) | 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白 | |
CN104837867A (zh) | 特异性结合tm4sf5蛋白的新型单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 201203 China (Shanghai) free trade zone Cailun Road, room 406 No. 781 Patentee after: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Address before: 201203, 10F, building 1, Heng International Building, 1238 Zhangjiang Road, Shanghai, Pudong New Area Patentee before: Obio Technology (Shanghai) Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160308 Address after: 201203, 10F, building 1, Heng International Building, 1238 Zhangjiang Road, Shanghai, Pudong New Area Patentee after: Obio Technology (Shanghai) Co.,Ltd. Address before: No. three, No. 5, Dongdan, Beijing, Dongcheng District Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200525 Address after: Room 208, No. 56 Beijing Zhonglu Complex Building, Yantai Economic and Technological Development Zone, Shandong Province Patentee after: Yantai Heyuan Edith Biomedical Technology Co.,Ltd. Address before: Room 406, No. 781, Cailun Road, China (Shanghai) pilot Free Trade Zone Patentee before: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240119 Address after: No.58, Beijing Middle Road, Yantai Development Zone, Yantai area, China (Shandong) pilot Free Trade Zone, Yantai City, Shandong Province 264006 Patentee after: Rongchang biopharmaceutical (Yantai) Co.,Ltd. Address before: 264006 room 208, complex building, No.56 middle Beijing Road, Yantai Economic and Technological Development Zone, Shandong Province Patentee before: Yantai Heyuan Edith Biomedical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |